Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
about
The incidence of herpes zoster in a United States administrative databaseEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsThe c-Abl tyrosine kinase regulates actin remodeling at the immune synapseQuality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylateT cell survival and function requires the c-Abl tyrosine kinaseAbelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophagesAbl tyrosine kinases in T-cell signalingImatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlationsThe effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathwaySmall-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.Multidermatomal herpes zoster.Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.Serratia marcessens infection presenting with papillovesicular rash similar to varicella zoster infection: a case report.
P2860
Q24549730-75D45056-46F4-4855-AC93-2F96FEB31FDCQ26749324-97FAEB17-D6E4-4CFE-81F4-6A80E45308DCQ26851417-4BBD239F-2FE4-4009-A016-6AF861408E46Q30482430-50D944D3-5708-437F-8759-D8095ED9158DQ35810733-93422549-B716-47AD-A2CF-01C77649CA42Q36125177-80615205-CEE1-4C78-8195-BD3E65BFC1ADQ36934732-B514F80C-C8C3-4071-BD0B-FCD1E7CF7808Q37182419-BB1D8E08-3AC9-4157-AF38-E131B204051AQ37326191-B8EE3D69-5E17-4581-BC99-906A6B6704E5Q37426727-BADC5246-3B7A-444A-AAC6-18FD22246E23Q37541654-160A61E1-CB46-43B8-8E26-9D246F8D41ABQ37842326-B9A9C652-5027-430F-877F-C272D932CDB4Q40602704-AD8E4439-32C8-4226-AEA6-53172DBA715BQ41091829-CE59F77B-E6EE-4145-9B94-A26B18D72D07Q42276725-D437FDCF-B9D3-49DB-9722-77E6CAC7A9D9Q54319050-9F54C255-83F5-4A85-BCBE-97E82CF30958
P2860
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Development of Varicella-Zoste ...... reated with imatinib mesylate.
@en
Development of Varicella-Zoste ...... reated with imatinib mesylate.
@nl
type
label
Development of Varicella-Zoste ...... reated with imatinib mesylate.
@en
Development of Varicella-Zoste ...... reated with imatinib mesylate.
@nl
prefLabel
Development of Varicella-Zoste ...... reated with imatinib mesylate.
@en
Development of Varicella-Zoste ...... reated with imatinib mesylate.
@nl
P2093
P1476
Development of Varicella-Zoste ...... treated with imatinib mesylate
@en
P2093
Alessandra Ferrajoli
Dimitrios Kontoyiannis
Francis J Giles
Gloria N Mattiuzzi
Hagop M Kantarjian
Issam Raad
James Reuben
Jianjin Shan
Jorge E Cortes
Mary Beth Rios
P304
P407
P577
2003-03-01T00:00:00Z